TL;DR: Ipamorelin is a synthetic pentapeptide that selectively triggers the pituitary gland to release growth hormone by binding the ghrelin receptor (GHS-R1a), without meaningfully raising cortisol, ACTH, or prolactin. This clean selectivity — verified in foundational 1998 research — is why it remains a benchmark GH secretagogue in laboratory studies today.
Ipamorelin has earned a reputation as one of the “cleanest” growth hormone releasing peptides (GHRPs) studied in the laboratory. Unlike earlier secretagogues, it selectively stimulates growth hormone (GH) release without meaningfully disturbing other hormones. This guide summarises what ipamorelin is, how it works, the research background behind it, and the handling considerations that matter when it is used strictly for research purposes only.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (five amino acids) that acts as a selective growth hormone secretagogue. It binds to the ghrelin receptor — formally the growth hormone secretagogue receptor (GHS-R1a) — located on somatotroph cells of the anterior pituitary gland, prompting those cells to release stored growth hormone.
Amino acid sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
It was first described in the late 1990s as part of a search for compounds that could reproduce the growth-hormone-releasing activity of earlier peptides while shedding their unwanted hormonal side effects. That selectivity is the single most cited reason ipamorelin remains a reference compound in GH secretagogue research today.
Because it mimics the action of ghrelin at the receptor level rather than acting as a growth-hormone-releasing hormone (GHRH), ipamorelin belongs to the GHRP family alongside GHRP-2, GHRP-6, and hexarelin — but with a markedly cleaner selectivity profile than any of them.
Mechanism of Action
Ipamorelin works through a defined, well-characterised pathway:
- Binds to GHS-R1a receptors on pituitary somatotrophs
- Activates intracellular signalling, including phospholipase C and calcium mobilisation
- Stimulates release of stored growth hormone
- GH enters circulation in a pulsatile manner that resembles the body’s own secretory rhythm
- 1
Binding
Ipamorelin binds GHS-R1a receptors on pituitary somatotrophs.
- 2
Signalling
Activates phospholipase C and calcium mobilisation inside the cell.
- 3
Release
Stored growth hormone is released from the somatotroph.
- 4
Circulation
GH enters the blood in a pulsatile rhythm resembling natural secretion.
The defining feature is selectivity. Older secretagogues such as GHRP-6 and GHRP-2 also raise cortisol, adrenocorticotropic hormone (ACTH), and prolactin to varying degrees, which complicates any study trying to isolate GH effects. In the studies that introduced ipamorelin, it produced a GH response comparable to GHRP-6 while leaving cortisol and prolactin essentially at baseline levels. This clean signal is why ipamorelin is frequently chosen as the GHS-R agonist of choice in mechanistic work.
Why Researchers Choose Ipamorelin
- Selective GH release — clean, dose-dependent GH pulses without significant cortisol or prolactin elevation
- Minimal appetite stimulation — unlike GHRP-6, it produces little of the strong hunger response driven by ghrelin receptor activation, allowing GH effects to be studied in isolation
- Predictable, reproducible response — the dose-response relationship is consistent, which makes experimental design more reliable
Research Background & Key Findings
The foundational study by Raun and colleagues (1998) characterised ipamorelin as “the first selective growth hormone secretagogue.” Working in animal models and isolated pituitary preparations, the group demonstrated a robust, dose-dependent GH release with a selectivity for GH over ACTH and cortisol that distinguished it clearly from the GHRP compounds that preceded it.
Subsequent laboratory work reinforced several consistent observations:
- Ipamorelin triggers pulsatile GH release rather than a sustained flat elevation, more closely reflecting natural secretory patterns.
- The GH response is dose-dependent across a defined range and reproducible between sessions.
- The selectivity profile — minimal impact on cortisol, ACTH, and prolactin — holds across the studied dose range, which is its principal research advantage.
For a broader picture of how GH secretagogues are grouped and compared, our overview of common peptide stacks places ipamorelin in context alongside related research compounds.
Comparison with Other GHRPs
| Peptide | GH Release | Cortisol | Prolactin | Appetite |
|---|---|---|---|---|
| Ipamorelin | Moderate | Minimal | Minimal | Minimal |
| GHRP-2 | Strong | Moderate | Moderate | Moderate |
| GHRP-6 | Strong | Moderate | Moderate | Strong |
| Hexarelin | Very Strong | High | High | Moderate |
Qualitative comparison from the research literature; higher bars carry larger off-target hormonal effects.
The table illustrates the trade-off that defines this class: the more potent secretagogues also carry the largest off-target hormonal effects, whereas ipamorelin trades a portion of raw potency for a much cleaner endocrine signal. At the potency extreme sits hexarelin, which produces the strongest GH release in this class alongside the largest hormonal trade-offs.
Ipamorelin in Combination Research
One of the most studied areas involving ipamorelin is its pairing with GHRH analogs. Growth hormone release is governed by two complementary inputs: GHRH, which drives synthesis and release, and ghrelin/GHS-R agonism, which amplifies the pulse. Because ipamorelin acts on the ghrelin pathway and GHRH analogs act on a separate receptor, the two are frequently co-administered in research to examine synergistic GH release that exceeds what either compound produces alone.
Commonly studied GHRH analog partners include:
- CJC-1295 — a widely referenced GHRH analog; see the CJC-1295 2mg research page
- Sermorelin — an alternative GHRH analog; see our what is sermorelin overview
- Modified GRF (1-29) — closely related to CJC-1295 without DAC
Some research settings use a pre-blended combination such as the CJC-1295 + Ipamorelin blend (5mg) to co-deliver both mechanisms. The rationale is mechanistic complementarity: GHRH analogs raise the baseline while the GHS-R agonist sharpens and amplifies the resulting pulse. Our guide to common peptide stacks covers this pairing in more detail.
Reconstitution & Handling Overview
Ipamorelin is typically supplied as a lyophilised (freeze-dried) powder that must be reconstituted with bacteriostatic water before use in the laboratory. The chosen concentration depends on the vial size and the experimental design. Ipamorelin research vials are commonly available in 2mg, 5mg, and 10mg presentations.
Reconstitution should follow careful aseptic technique: bacteriostatic water is added slowly against the vial wall rather than directly onto the powder, and the vial is swirled gently — never shaken — until fully dissolved. For a full step-by-step walkthrough, see our peptide reconstitution guide. Handling and administration technique for research models are covered in our injection best practices article.
Research Dosing Considerations
The figures below reflect general ranges reported in the research literature and are provided for educational context only. They are not medical instructions and are not intended for human use.
| Protocol | Dose | Frequency |
|---|---|---|
| Low | 100mcg | 2-3x daily |
| Standard | 200mcg | 2-3x daily |
| Higher | 300mcg | 2-3x daily |
A frequently noted consideration in the literature is that GH secretagogues tend to produce a cleaner pulse when administered away from food, since elevated blood glucose and fatty acids can blunt the GH response. Studies commonly space administration to align with the natural pulsatile rhythm of GH secretion. Any specific protocol should be defined by the research design and applicable oversight, not by generalised figures.
Storage & Stability
Proper storage preserves peptide integrity and is essential for reproducible research:
- Lyophilised powder: store at -20°C for long-term stability; the freeze-dried form is relatively robust
- Reconstituted solution: store at 2-8°C (refrigerated), protected from light
- Reconstituted stability: generally 3-4 weeks when kept refrigerated
- Avoid repeated freeze-thaw cycles of the reconstituted solution, and never expose vials to direct heat or prolonged light
For general storage principles that apply across research peptides, see our peptide storage guide.
Safety, Legality & Research Disclaimers
Ipamorelin is a research peptide. It is not an approved medicine and has not been authorised for therapeutic use in humans. It should be treated strictly as a laboratory research chemical, handled by qualified individuals in an appropriate setting, and used only for legitimate research purposes.
Regulatory status varies by jurisdiction, and researchers are responsible for confirming that their acquisition, possession, and use comply with all applicable local laws and institutional requirements. Nothing in this article constitutes medical advice or an endorsement of use in humans or animals outside of properly sanctioned research.
Sourcing & Quality Verification for Research
Because research outcomes depend on knowing exactly what is in the vial, quality verification is a core part of responsible sourcing. When evaluating a research peptide, look for the following generic markers of quality rather than marketing claims:
- Third-party analytical testing — independent laboratory confirmation of identity and purity
- Certificate of Analysis (COA) — documentation reporting purity (commonly by HPLC) and identity (commonly by mass spectrometry) for the specific product
- Batch traceability — a lot or batch number linking the physical vial to its corresponding test data
- Consistent presentation — properly lyophilised material, intact seals, and clear labelling of peptide identity and mass
A purity figure is only meaningful when it is tied to a specific, traceable batch and issued by an independent laboratory. These verification steps apply to any research peptide, ipamorelin included. For a closer look at reading a COA and interpreting purity data, see our guide to understanding peptide purity and COAs.
FAQ
Is ipamorelin the same as a GHRH like CJC-1295?
No. Ipamorelin is a ghrelin receptor (GHS-R1a) agonist — a growth hormone secretagogue. CJC-1295 is a GHRH analog that acts on a different receptor. They work through complementary pathways, which is precisely why they are studied together.
Why is ipamorelin called “selective”?
Because it stimulates growth hormone release with minimal effect on cortisol, ACTH, and prolactin. Earlier GHRPs such as GHRP-2 and GHRP-6 raise those hormones to varying degrees, whereas ipamorelin leaves them close to baseline in the studies that characterised it.
Does ipamorelin increase appetite?
In research models it produces markedly less appetite stimulation than GHRP-6, which strongly activates hunger via the ghrelin pathway. This makes ipamorelin useful for isolating GH-specific effects.
How is ipamorelin stored?
The lyophilised powder is kept at -20°C for long-term storage. Once reconstituted with bacteriostatic water, it is refrigerated at 2-8°C, protected from light, and generally used within 3-4 weeks.
Can ipamorelin be used in humans?
No. It is a research peptide, not an approved medicine, and is intended for laboratory research purposes only. It has not been authorised for human therapeutic use.
References
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998.
- Research literature on GHRH analog and growth hormone secretagogue co-administration for synergistic growth hormone release.
Last updated: July 4, 2026
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption. For detailed reconstitution instructions, see our Ipamorelin Dosage Guide.